Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{56c03c229cb24ef087ff5b0021eff39e,
title = "Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry",
abstract = "To compare tumor necrosis factor alpha inhibitors directly regarding the rates of treatment response, remission, and the drug survival rate in patients with rheumatoid arthritis (RA), and to identify clinical prognostic factors for response.",
author = "Hetland, {Merete Lund} and Christensen, {Ib Jarle} and Ulrik Tarp and Lene Dreyer and Annette Hansen and Hansen, {Ib T{\o}nder} and Kollerup, {Gina Birgitte} and Louise Linde and Lindegaard, {Hanne Merete} and Poulsen, {Uta Engling} and Annette Schlemmer and Jensen, {Dorte Vendelbo} and Signe Jensen and Gisela Hostenkamp and Mikkel {\O}stergaard and {All Departments of Rheumatology in Denmark}",
year = "2010",
month = "1",
day = "1",
doi = "10.1002/art.27227",
language = "English",
volume = "62",
pages = "22--32",
journal = "Arthritis and Rheumatism",
issn = "0004-3591",
publisher = "John/Wiley & Sons, Inc. John/Wiley & Sons Ltd",
number = "1",

}

RIS

TY - JOUR

T1 - Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry

AU - Hetland, Merete Lund

AU - Christensen, Ib Jarle

AU - Tarp, Ulrik

AU - Dreyer, Lene

AU - Hansen, Annette

AU - Hansen, Ib Tønder

AU - Kollerup, Gina Birgitte

AU - Linde, Louise

AU - Lindegaard, Hanne Merete

AU - Poulsen, Uta Engling

AU - Schlemmer, Annette

AU - Jensen, Dorte Vendelbo

AU - Jensen, Signe

AU - Hostenkamp, Gisela

AU - Østergaard, Mikkel

AU - All Departments of Rheumatology in Denmark

PY - 2010/1/1

Y1 - 2010/1/1

N2 - To compare tumor necrosis factor alpha inhibitors directly regarding the rates of treatment response, remission, and the drug survival rate in patients with rheumatoid arthritis (RA), and to identify clinical prognostic factors for response.

AB - To compare tumor necrosis factor alpha inhibitors directly regarding the rates of treatment response, remission, and the drug survival rate in patients with rheumatoid arthritis (RA), and to identify clinical prognostic factors for response.

U2 - 10.1002/art.27227

DO - 10.1002/art.27227

M3 - Journal article

VL - 62

SP - 22

EP - 32

JO - Arthritis and Rheumatism

JF - Arthritis and Rheumatism

SN - 0004-3591

IS - 1

ER -

ID: 32219357